Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
14.59
-0.15 (-1.02%)
May 29, 2026, 4:00 PM EDT - Market closed
Janux Therapeutics Stock Forecast
Stock Price Forecast
According to 18 analysts polled by S&P Global, Janux Therapeutics stock has a consensus rating of "Buy" and an average price target of $40.56. The average 1-year stock price forecast is 178.00% higher than the current stock price, while the lowest is $14 (-4.04%) and the highest is $80 (+448.32%).
Price Target: $40.56 (+178.00%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Janux Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 15 | 14 | 14 | 13 | 13 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 18 | 18 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI | Evercore ISI | Buy Maintains $23 → $22 | Buy | Maintains | $23 → $22 | +50.79% | May 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $45 | Buy | Reiterates | $45 | +208.43% | May 11, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $60 | Buy | Reiterates | $60 | +311.24% | May 8, 2026 |
| Wedbush | Wedbush | Buy Reiterates $45 → $36 | Buy | Reiterates | $45 → $36 | +146.74% | May 8, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $68 → $58 | Buy | Reiterates | $68 → $58 | +297.53% | May 8, 2026 |
Financial Forecast
Revenue This Year
21.63M
from 10.00M
Increased by 116.34%
Revenue Next Year
5.35M
from 21.63M
Decreased by -75.28%
EPS This Year
-2.21
from -1.83
EPS Next Year
-3.03
from -2.21
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 60.4M | 36.8M | ||||||
| Avg | 21.6M | 5.3M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 503.7% | 69.9% | ||||||
| Avg | 116.3% | -75.3% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.71 | -2.16 | ||||||
| Avg | -2.21 | -3.03 | ||||||
| Low | -2.92 | -3.43 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.